The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== Prediction and analysis of drug targets === RNApred: Prediction of RNA binding proteins from its amino acid sequence. ProPrint: Prediction of interaction between proteins from their amino acid sequence. DomPrint: A domain-domain interaction (DDI) prediction server. MycoPrint: A web interface for exploration of the interactome of Mycobacterium tuberculosis H37Rv (Mtb) predicted by the "Domain Interaction Mapping" (DIM) method. ATPint: A server for predicting ATP interacting residues in proteins. FADpred: Identification of FAD interacting residues in proteins. GTPbinder: Prediction of protein GTP interacting residues. NADbinder: Prediction of NAD binding residues in proteins. PreMier: Software for predicting mannose interacting residues in proteins. DMAP: Designing of mutants of antibacterial peptides. icaars: Prediction and classification of aminoacyl tRNA synthetases using PROSITE domains. CBtope: Prediction of conformational B-cell epitope in a sequence from its amino acid sequence. DesiRM: Designing of Complementary and Mismatch siRNAs for silencing a gene. GenomeABC: A server for benchmarking of genome assemblers.
== Revocation of nursing license == After the incident, the Tennessee Board of Nursing reviewed Vaught's case and initially rendered "a decision that [the] matter did not merit further action." However, In September 2019, the Tennessee Department of Health's Board of Nursing reversed their decision, charging Vaught with three infractions: unprofessional conduct, abandoning or neglecting a patient who required care, and failing to maintain an accurate patient record. In July 2021, the nursing board revoked Vaught's license and fined her $3,000. During her testimony, she took responsibility for the error, but also described procedural issues at the hospital. "Overriding was something we did as a part of our practice every day. You couldn't get a bag of fluids for a patient without using an override function." The Institute for Safe Medication Practices called the board decision "disturbing and unjust." It alleged that the decision reflected "significant outcome bias," "inability to differentiate between human error, at-risk behavior, and reckless behavior," "lack of a thorough investigation," and other shortcomings.
Studies on gender and health remain limited. In the early 21st century, life expectancy in France was higher for women than men—85.3 years compared to 79.4 in 2018. However, healthy life expectancy was similar, with women at 64.5 years and men at 63.4 in 2018. Since 2004, healthy life expectancy has increased for men but remained stable for women. Historically, in Western societies, male and female health have been conceptualized differently. From Antiquity onward, the male body was viewed as the standard, while the female body was seen as a variation and more prone to illness. Diagnoses and treatment have differed depending on the patient's sex. In 17th- and 18th-century Europe, women were more often diagnosed with nervous disorders. During this period, medical and state interests in reproduction led to increased study of the female body, particularly as a reproductive body, with a focus on the uterus. New professions, such as midwifery and obstetrics, developed in this context. From the late 18th century onward, sexuality began to be medicalized. Behavioral norms were reframed in medical rather than religious terms, with differences in how male and female behavior were judged. For a prolonged period, women's bodies and intellects were considered inferior in medical discourse, contributing to gendered hierarchies. Women's health was often regarded as pathological or dysfunctional by default. Scientific research has also been shaped by gender bias.
Sources: en.wikipedia.org
==== August ==== On 3 August, what the transitional government called "illegal groups" reportedly violated the ceasefire agreement and attacked the Syrian Internal Security Forces. Fighting took place in Tal al-Hadid, with the Al-Jabal Brigade involved in the fighting. On 8 August, clashes erupted in the town of Najran between Druze factions and an armed group, following an attack reportedly launched by the latter. The Syrian Observatory for Human Rights reported that the clashes resulted in the deaths of two people on both sides, along with material damage and the burning of several civilian homes, before the attackers withdrew. On 10 August, the town of al-Majdal came under an assault from three directions, involving the use of heavy machine guns and mortar fire. One wave of the attack originated from the town of al-Mazraa, where government forces are stationed, while the other two approached from positions west of al-Majdal, firing heavy and medium machine guns toward the surrounding villages. On 15 August, one woman from Suwayda was killed when unidentified armed assailants opened fire on the vehicle she was traveling in near the town of al-Kiheel in the eastern countryside of Daraa Governorate. She was en route with other passengers from Suwayda to Beirut via the highway passing through Daraa toward Damascus. The area where the incident took place was under the control of the Syrian government. On 16 August, demonstrations took place in al-Karama Square in Suwayda.
=== Valuation === Theranos raised millions of dollars in its first years. In 2004, Theranos was based in a rented basement near the Stanford campus. By December 2004, the company had raised more than $6 million from investors at a valuation of $30 million. The company had about $45 million total fundraising after Series B and Series C funding in 2006. Theranos raised an additional $45 million in 2010 at a valuation of $1 billion. The company had significant news coverage starting in September 2013 after profiles in the San Francisco Business Times and The Wall Street Journal. By 2014, Theranos had raised more than $400 million with an estimated value of $9 billion. Theranos raised more than $700 million from venture capitalists and private investors, resulting in a $10 billion valuation at its peak in 2013 and 2014. In 2016, Forbes revised the estimated net worth of the company to $800 million taking into account the $724 million of capital raised. Between 2004 and 2016, the amount of available cash from investors for private equity/venture capital firms to invest in companies grew from $400 billion to $1.5 trillion. It was a period of plentiful capital available where investors were pressured to find investment targets to deploy capital on. In the Theranos case, insufficient due diligence and fraudulent business practices led to the losses for investors. In May 2017, participating shareholders provided a release of any potential claims against Theranos in exchange for shares of the company's new preferred stock.
== Interactions == Interactions with atenolol include catecholamine-depleting drugs like reserpine, calcium channel blockers, disopyramide, amiodarone, clonidine, prostaglandin synthase inhibitors like indomethacin, and digitalis glycosides. Most of these interactions involve either additive cardiovascular effects or reduction of atenolol's effects. Atenolol is mainly eliminated renally without being metabolized by the liver or by cytochrome P450 enzymes. As a result, it has little or no potential for cytochrome P450-related drug interactions, for instance with inhibitors and inducers of these enzymes. Accordingly, the broad/non-selective cytochrome P450 inhibitor cimetidine had no effect on atenolol levels, whereas cimetidine has been found to significantly increase metoprolol and propranolol levels. Beta blockers like atenolol can reduce or block the cardiovascular effects of sympathomimetics and amphetamines, such as hypertension and tachycardia. Atenolol has been found to be safe in combination with the non-selective monoamine oxidase inhibitor (MAOI) phenelzine and actually improved orthostatic hypotension and hypertensive reactions with phenelzine. However, more research is still needed to assess whether addition of a beta blocker like atenolol to MAOI therapy is safe and effective for improving orthostatic hypotension with MAOIs.
In a clinical trial, the rate of systolic orthostatic hypotension was 21% versus 9% with placebo and the rate of diastolic orthostatic hypotension was 12% versus 4% with placebo in people with Parkinson's disease taking the ODT form of selegiline. The risk of hypotension is greater at the start of treatment and in the elderly (3% vs. 0% with placebo). The rate of hypotension or orthostatic hypotension with the selegiline patch was 2.2% versus 0.5% with placebo in clinical trials of people with depression. Significant orthostatic blood pressure changes (≥10 mm Hg decrease) occurred in 9.8% versus 6.7% with placebo, but most of these cases were asymptomatic and heart rate was unchanged. The rates of other orthostatic hypotension-related side effects in this population were dizziness or vertigo 4.9% versus 3.1% with placebo and fainting 0.5% versus 0.0% with placebo. It is said that orthostatic hypotension is rarely seen with the selegiline transdermal patch compared to oral MAOIs. Caution is advised against rapidly rising after sitting or lying, especially after prolonged periods or at the start of treatment, as this can result in fainting. Falls are of particular concern in the elderly. MAOIs like selegiline may lower blood pressure by increasing dopamine levels and activating dopamine receptors, by increasing levels of the false neurotransmitter octopamine, and/or by other mechanisms. Meta-analyses published in the 1990s found that the addition of selegiline to levodopa increased mortality in people with Parkinson's disease.
Sources: en.wikipedia.org
=== 1960s–1990s === In 1960, Rogers asked to buy into Toddle House, and was subsequently refused. Afterwards, he moved back to Atlanta and rejoined Waffle House, now a chain of three restaurants, to run restaurant operations. Shortly after Rogers returned full-time, Forkner followed suit and left Ben S. Forkner Realty. After opening a fourth restaurant in 1960, the company began franchising its restaurants and slowly grew to 27 stores by the late 1960s, before growth accelerated.
== Behavior == Male and female king bettas flare or puff out their gills in order to appear more impressive, either to intimidate rivals or attract mates, as well as when they are startled. Females often flare their gills at other females (rare in B. splendens.) All bettas require a place to hide occasionally, even in solitary tanks. They may set up a territory centered on a plant or rock, which they will guard aggressively. This breed is not appropriate for a typical community tank due to its aggressiveness, particularly towards species of fish with long, flowing fins.
=== Plot === The game begins with Chell waking up from a stasis bed and hearing instructions from GLaDOS, an artificial intelligence, about upcoming tests. Chell enters into sequential distinct chambers that introduce her to varying challenges to solve using her portal gun, with GLaDOS as her only interaction. GLaDOS promises cake as a reward for Chell if she completes all the test chambers. As Chell nears completion, GLaDOS's motives and behavior turn more sinister, suggesting insincerity and callous disregard for the safety and well-being of test subjects. The test chambers become increasingly dangerous as Chell proceeds, including a live-fire course designed for military androids, as well as chambers flooded with a hazardous liquid. In one chamber, GLaDOS forces Chell to "euthanize" a Weighted Companion Cube in an incinerator, after Chell uses it for assistance. After Chell completes the final test chamber, GLaDOS maneuvers Chell into an incinerator in an attempt to kill her. Chell escapes with the portal gun and makes her way through the maintenance areas within the Enrichment Center. GLaDOS panics and insists that she was pretending to kill Chell as part of testing, while it becomes clear that GLaDOS had previously killed all the inhabitants of the center. Chell travels further through the maintenance areas, discovering dilapidated backstage areas covered in graffiti that includes statements such as "the cake is a lie", and pastiches of quotes from famous poets such as Henry Wadsworth Longfellow and Emily Brontë.
The mean is T and the variance is zero. The RTD of a real reactor deviates from that of an ideal reactor, depending on the hydrodynamics within the vessel. A non-zero variance indicates that there is some dispersion along the path of the fluid, which may be attributed to turbulence, a non-uniform velocity profile, or diffusion. If the mean of the distribution is earlier than the expected time T it indicates that there is stagnant fluid within the vessel. If the RTD curve shows more than one main peak it may indicate channeling, parallel paths to the exit, or strong internal circulation. In PFRs, reactants enter the reactor at one end and react as they move down the reactor. Consequently, the reaction rate is dependent on the concentrations which vary along the reactor requiring the inverse of the reaction rate to be integrated over the fractional conversion.
Daniel Levy (political analyst); analyst, commentator, author, journalist, former advisor to Israeli government; formerly Israeli negotiator Taba summit and Oslo 2 peace process; current president of U.S./Middle East Project (USMEP); among founders of J Street; son of Lord Michael Levy; was World Chairman of World Union of Jewish Students in Jerusalem; served in Israel Defense Forces (IDF) as non-commissioned officer; worked as head of Jerusalem Affairs unit under Minister Haim Ramon; served as advisor to Justice Minister Yossi Beilin; served as an Israeli negotiator in peace talks with Palestinian leaders during his IDF years under Israeli Prime Ministers Yitzhak Rabin and Ehud Barak; was lead drafter of 2003 Geneva Initiative along with Ghaith al-Omari; current president of the U.S./Middle East Project He previously headed the Middle East and North Africa program at the European Council on Foreign Relations from 2012 to 2016. He has also worked at the director level on the New America Foundation's Middle East Task Force and as a fellow with the Century Foundation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.